[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-cutaneous-gamma-delta-t-cell-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":30,"states":31},"Primary Cutaneous Gamma-Delta T-Cell Lymphoma",3,2,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05475925","A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:27.068416Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05978141","A Registry for People With T-cell Lymphoma",[],"2026-08-26T02:16:20.336282Z","2026-05-13T02:55:06.403613Z",{"nct_id":23,"title":24,"phases":25,"status":27,"updated_at":28,"content_modified":29},"NCT07691450","Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma",[26],"Phase 1","NOT_YET_RECRUITING","2026-08-26T02:16:42.787115Z","2026-07-19T19:36:05.157190Z",[],[32],{"state":33,"count":5,"slug":34},"California","california"]